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Background and objective: We have explored whether assessing the degree of concavity 
in the descending limb of the maximum expiratory flow–volume curve enhanced spirometric 
detection of early small airway disease.
Methods: We used spirometry records from 890 individuals aged $40 years (mean 59 years), 
recruited for the Burden of Obstructive Lung Disease Australia study. Central and peripheral 
concavity indices were developed from forced expired flows at 50% and 75% of the forced vital 
capacity, respectively, using an ideal line joining peak flow to zero flow.
Results: From the 268 subjects classified as normal never smokers, mean values for post-
bronchodilator central concavity were 18.6% in males and 9.1% in females and those for 
peripheral concavity were 50.5% in males and 52.4% in females. There were moderately strong 
correlations between concavity and forced expired ratio (forced expiratory volume in 1 second/
forced vital capacity) and mid-flow rate (forced expiratory flow between 25% and 75% of the 
FVC [FEF
25%–75%
]; r=-0.70 to -0.79). The additional number of individuals detected as abnormal 
using the concavity indices was substantial, especially compared with FEF
25%–75%
, where it was 
approximately doubled. Concavity was more specific for symptoms.
Conclusion: The inclusion of these concavity measures in the routine reports of spirometry 
would add information on small airway obstruction at no extra cost, time, or effort.
Keywords: early airway disease, airflow obstruction, COPD
Plain language summary
This study investigated whether assessing the concave pattern of the flow–volume curve was 
more reliable than conventional spirometric indices for detecting early small airway obstruc-
tion. We compared conventional spirometric indices with the degree of concavity in 890 
individuals, aged $40 years, recruited for the Burden of Obstructive Lung Disease Australia 
study. We found that the prevalence of abnormal spirometry was far higher for concavity than 
for conventional indices. We also found that concavity was more specific for breathlessness 
on moderate exercise. We conclude that there is more information in spirometry than is being 
currently used, which might be valuable in detecting early airway disease.
Introduction
COPD is characterized by airflow obstruction which is slowly progressive and not 
fully reversible.1 The core pathophysiology is in the small airways with obstruction 
caused by wall fibrosis and progressive obliteration of the lumen.2 Emphysema may 
later occur and will then contribute to airflow obstruction.2–4 Clinical guidelines 
advocate the measurement of spirometry in people suspected of having the disease 
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and emphasize spirometry’s importance in the early detection 
to arrest disease progression,1,5 using the ratio of the forced 
expiratory volume in 1 second to the forced vital capacity 
(FEV
1
/FVC). However, these spirometric measures may 
not be best for detecting small airway changes. There is a 
need for better measures of airflow obstruction, and it has 
long been recognized that there is more information in the 
expiratory flow–volume curve than is currently utilized in 
routine practice. The current advances in spirometers make 
it entirely feasible to easily access this information, and we 
have explored one approach to this goal.
The functional information provided by the FEV
1
 is 
necessarily limited to detecting abnormal flows during the 
first second of the expiratory maneuver when the lung is rela-
tively inflated and the thin-walled elastic small airways are 
exposed to significant distending forces. Consequently, dur-
ing the first second, the contribution from the small airways to 
total airway resistance is limited unless advanced generalized 
small airway narrowing is present and would not particularly 
be sensitive to abnormalities caused by early small airway 
lesions.2,6,7 In contrast, the maximal expiratory flow–volume 
(MEFV) curve represents a complete description of maximum 
flows and includes the region beyond 1 second where the lung 
is less inflated and the airway distending forces are lower, 
resulting in progressive narrowing as lung volume falls.
Furthermore, it has long been recognized that the first 
indication of abnormal ventilatory function is the develop-
ment of concavity in the tail of the curve, and this is explicitly 
acknowledged in the American Thoracic Society/European 
Respiratory Society statement on the interpretation of lung 
function.8 Indeed, this is supported by the equal pressure 
point concept9 and modeling based on the wave speed theory 
of airflow limitation,10 which found that the segment of 
airways limiting expiratory flow moved progressively into 
smaller airways as lung volume decreased. This suggests that 
reduced flows, isolated in the tail of the MEFV curve, were 
more specific to earliest small airway dysfunction. Based on 
these insights, newer methods have been developed11,12 but 
are complex and have not yet been translated widely into 
clinical or research practice.
It is generally agreed that the major underlying mecha-
nism causing concavity is volume-dependent nonuniform 
airway emptying.13,14 This occurs when lung compartments 
have widely differing expiratory time constants, as would 
be expected in obstructive lung disease with small airway 
dysfunction, with the fastest and slowest emptying compart-
ments contributing disproportionally to expiratory flows 
as the lung empties. In the early stages of COPD disease, 
distribution is patchy14 causing an increase in nonuniform 
airway emptying and the development of a concave-shaped 
MEFV curve. Hence, we suggest that the first indication of 
early airflow obstruction is the appearance of concavity, 
which is in agreement with other measures.8,13,14–17
A number of studies have investigated this concave pattern 
of the MEFV curve and concluded that the presence of a con-
cavity was closely associated with airflow obstruction,13,18,19 
even when the FEV
1
 was normal,20,21 and correlated with 
spirometric indices of small airway obstruction.22 Concavity 
correlated better with symptom scores in childhood asthma 
than FEV
1
 and FEV
1
/FVC,18 was able to differentiate between 
healthy adults and mild COPD,23 and was sensitive to bronchi-
olitis and its severity following lung transplantation.24 These 
and other studies have used a number of methods to assess 
curvature of the MEFV curve: 1) the slope ratio introduced 
by Mead,13 which is based on instantaneous tangents slopes 
measured at multiple points along the descending curve; 2) 
angle β, which is the angle subtended between two lines 
drawn from mid vital capacity to residual volume (RV) 
and peak expiratory flow (PEF) at total lung capacity;25 3) 
the average curvature index, which is a multistep method 
requiring data smoothing and fitting a quadratic function to 
the curve;18 and 4) Kmax, a complex global curvature index 
obtained by fitting a hyperbolic function.19 Other less-specific 
methods have included the area under the MEFV curve26 and 
analysis of expiratory flow patterns against time.27 However, 
these methods have been complex and difficult to apply rou-
tinely, have not been evaluated in a community sample of 
adults, and none of them have been incorporated into routine 
spirometry software or clinical guidelines.
We recently reported a preliminary analysis of two new 
but simple indices of concavity (central and peripheral) and 
showed that the prevalence of abnormal concavity in the 
general population was, as perhaps expected, higher than that 
estimated using the FEV
1
/FVC ratio.28 In the current study, we 
report more detailed analysis of concavity in a random sample 
of people aged $40 years from the Burden of Obstructive 
Lung Disease (BOLD) Australia study.29 We have assessed 
the reliability of a new measure of concavity and its validity as 
an indicator of mild airway obstruction in this population.
Methods
This is an analysis of data collected in a randomly selected 
sample of subjects aged $40 years living in Victoria and 
Tasmania who participated in the Australian part of the 
BOLD initiative.29 Subjects underwent pre-bronchodilator 
(pre-BD) and post-bronchodilator (post-BD) spirometry with 
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flow–volume curves. With the assistance of an interviewer, 
they completed the standardized BOLD questionnaire.30 
We assessed MEFV curves to quantify the degree of central 
and peripheral concavities (detailed below), produced upper 
limits of normal, and described the prevalence of an abnormal 
degree of concavity in our sample compared with standard 
spirometric measurements.
ethics approval
The study was approved by the Human Research Ethics 
Committee of the University of Sydney (ref no 12-2006/9724). 
Additionally, the Tasmania and Melbourne sites obtained local 
ethics approval from Tasmania Health and Medical Human 
Research Ethics Committee (Ref: H0009637) and The Alfred 
Hospital Ethics Committee (Ref: 118/08), respectively. All 
participants gave written informed consent for this study.
spirometry
Spirometry was performed according to the European 
Respiratory Society standard31 using the ultrasonic EasyOne 
spirometer (ndd Medizintechnik, Zürich, Switzerland). This 
spirometer was chosen because it is accurate, retains accuracy 
during extended use,32 and provides automatic grading of test 
quality with feedback to the tester. Spirometry was measured 
before and after 15 minutes of the administration of 200 µg 
salbutamol. At least three pre-BD and three post-BD trials 
were performed. Only curves that met acceptability criteria 
and were repeatable to within ±0.2 L for both FEV
1
 and FVC 
were included. The highest values for FEV
1
 and FVC from 
acceptable curves were used.31
Central and peripheral concavities
The method used to quantify the degree of concavity has been 
described previously.28 In brief, our central and peripheral 
indices of concavity were based on the forced expiratory flow 
measured at the point where 50% (FEF
50%
) and 75% (FEF
75%
) 
of the FVC had been expired, respectively (Figure 1). The 
degree of concavity was expressed as the percentage decrease 
of these measured flows from the corresponding “ideal” 
reference flows calculated by assuming that the descending 
limb had no curvature (ie, was a straight line, see Figure 1), 
a general finding in normal adult spirometry.33 The FEF
50%
 
and FEF
75%
 were taken from the single acceptable trial with 
the highest FEV
1
. The value of volume expired to peak 
expiratory flow (vPEF; Figure 1) was measured manually 
from the MEFV curve, but assuming a fixed value equal to 
the mean values obtained in this study (0.65 L in males and 
0.51 L in females) introduced a small error.
The post-BD upper limit of normal (ULN) for central 
and peripheral concavities were derived separately for 
males and females who met the following criteria: lifelong 
non-smokers; ,12% change in either FEV
1
 or FVC post 
bronchodilator; no diagnosis of asthma, emphysema, COPD, 
or chronic bronchitis by physician; and not limited in per-
forming moderate exercise.
In the BOLD questionnaire, the assessment of current 
health-limiting exercise capacity was according to whether 
capacity to perform “moderate” daily activities (eg, pushing 
a vacuum cleaner, moving a table) was “not limited at all”, 
“limited a little”, or “limited a lot”. Since there were few 
responses in this latter group, we have combined the last two 
groups to provide separate male and female data. Spirometry 
and concavity were compared by quantifying their sensitivity 
and specificity for detecting exercise limitation.
statistical analysis
Data were expressed as a percentage or mean ± SD for 
continuous variables. Two-tailed t-test, assuming unequal 
variances, was used to assess differences between means. 
A probability of #5% was taken as significant. Spirometric 
reference equations from Hankinson et al34 were used to 
obtain % predicted. Spearman’s rank correlation was used 
to determine the relationship between indices of concavity 
and spirometric values. The ULNs for central and peripheral 
concavities were determined separately for normal male and 
female subjects as the 95th percentile. Correlations were 
used to assess repeatability. Reliability was assessed as the 
intraclass (within-subject) correlation. We used exercise 
limitation due to dyspnea as an independent indicator of 
Figure 1 Variables used to quantify central and peripheral concavities (see text).
Notes: FeF50% and FeF75% are the measured values and ref FeF50% and ref FeF75% 
are the reference flows that would be obtained if the flow–volume curve had zero 
curvature, that is, a linear descending limb (dashed line).
Abbreviations: FeF25%–75%, forced expiratory flow between 25% and 75% of the 
FVC; FVC, forced vital capacity; PEF, peak expiratory flow; vPEF, volume expired 
to peak expiratory flow.
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the presence of (cardio)respiratory disease and assessed 
the validity of the new measures of concavity (central and 
peripheral concavities . ULN) and the established measures 
(FEV
1
/FVC, FEV
1
, and forced expiratory flow between 25% 
and 75% of the FVC [FEF
25%–75%
] , lower limit of normal 
[LLN]) by quantifying their sensitivity and specificity for 
this functional limitation.
Results
Demographics and descriptive spirometry
Descriptive data for males (n=424) and females (n=466) 
are summarized in Table 1. By design of the BOLD study, 
the sample was middle-aged and older (range, 40–87) with 
a mean age of 59 years. Overall, males had significantly 
more central (P,0.001) and higher FEF
25%–75%
 (expressed 
as percent predicted, P=0.001) than females, but peripheral 
concavity and FEV
1
/FVC ratio were similar.
A higher proportion of males than females had ever 
smoked and had a higher lifetime tobacco consumption 
(median pack-years: males, 17.8; females, 10.3, P,0.001). 
Participants who had ever smoked had significantly lower 
values for FEV
1
/FVC, FEV
1
, and FEF
25%–75%
, and a greater 
degree of central concavity and in males, peripheral con-
cavity also, when compared with those who had never 
smoked. However, in females, peripheral concavity was 
similar between ever and never smokers. Smoking history 
had little effect on spirometry or degree of concavity up 
to approximately a 10 pack-year history in females and 
a 20 pack-year history in males, but above these levels, 
there was a significant decrease in FEV
1
, FEV
1
/FVC, and 
FEF
25%–75%
, and a greater degree of central and peripheral 
concavities (Figure 2).
Following the administration of salbutamol, there was 
a significant increase in FEV
1
, FEV
1
/FVC, and FEF
25%–75%
, 
Table 1 Descriptive data for the sample
Males Females
All males Never smoked Ever smoked All females Never smoked Ever smoked
subjects, n (% by gender) 424 199 (46.9) 225 (53.1) 466 237 (50.9) 229 (49.1)
age, years: mean (sD) 59.0 (11.0) 57.0 (10.8) 60.7 (10.9) 58.4 (10.5) 59.5 (10.4) 57.2 (10.5)
height, cm: mean (sD) 175.2 (6.6) 176.1 (6.5) 174.3 (6.6) 161.8 (6.5) 161.8 (6.3) 161.9 (6.7)
Weight, kg: mean (sD) 86.7 (14.8) 86.6 (14.8) 86.9 (14.8) 71.9 (14.4) 71.4 (14.4) 72.4 (14.4)
BMI, kg/m2: mean (sD) 28.2 (4.3) 27.9 (4.2) 28.6 (4.4) 27.4 (5.2) 27.2 (5.1) 27.6 (5.2)
Pack-year history: median (95% CI) 17.8 (14.2–21.4) 10.3 (8.1–12.4)
Pre-BD spirometry: mean (sD)
FeV1, l 3.35 (0.79) 3.57 (0.78) 3.16 (0.76) 2.43 (0.60) 2.46 (0.55) 2.41 (0.60)
% predicted 95.5 (15.3) 98.6 (14.6) 92.8 (15.4)b 95.0 (15.6) 97.2 (15.5) 92.7 (15.4)b
FVC, l 4.45 (0.91) 4.66 (0.89) 4.27 (0.89) 3.21 (0.67) 3.21 (0.68) 3.22 (0.67)
% predicted 96.4 (13.0) 98.3 (12.7) 94.8 (13.1)b 97.8 (13.4) 98.6 (14.0) 97.0 (12.7)
FeV1/FVC% 75.0 (8.2) 76.4 (7.3) 73.8 (9.0) 75.5 (7.8) 76.5 (7.2) 74.5 (8.3)
% predicted 98.9 (10.3) 100.2 (9.0) 97.7 (11.2)b 96.3 (9.6) 97.9 (8.9) 94.7 (10.1)b
FeF25%–75%, l/second 2.88 (1.25) 3.21 (1.26) 2.58 (1.16) 2.12 (0.93) 2.20 (0.85) 2.05 (0.99)
% predicted 97.6 (37.3) 104.0 (35.1) 91.9 (38.4)b 88.9 (35.1) 94.3 (32.7) 83.4 (36.8)b
Post-BD spirometry: mean (sD)
FeV1, l 3.47 (0.78) 3.70 (0.76) 3.26 (0.74) 2.51 (0.58) 2.53 (0.56) 2.49 (0.60)
% predicted 98.9 (14.8)a 102.4 (14.1) 95.8 (14.8)b 98.0 (14.8)a 100.1 (14.8) 95.8 (14.6)b
FVC, l 4.48 (0.87) 4.69 (0.86) 4.29 (0.84) 3.22 (0.66) 3.21 (0.67) 3.23 (0.66)
% predicted 97.2 (12.5) 99.1 (12.1) 95.5 (12.7)b 98.0 (12.7) 98.6 (13.5) 97.3 (11.8)
FeV1/FVC% 77.2 (8.1)
a 78.7 (7.15) 75.8 (8.7) 77.9 (7.9) 78.8 (6.9) 76.9 (8.6)
% predicted 101.7 (10.2) 103.2 (8.9) 100.3 (11.1)b 99.3 (9.6)a 100.9 (8.5) 97.7 (10.4)b
FeF25%–75%, l/second 3.24 (1.35) 3.63 (1.32) 2.90 (1.28) 2.45 (1.01) 2.53 (0.91) 2.38 (1.11)
% predicted 110.4 (40.8)a 118.4 (38.1) 103.3 (42.0) 102.6 (38.2)a 108.2 (34.2) 96.9 (41.3)b
Pre-BD concavity: mean (sD)
Central, % 31.2 (21.7)a 28.2 (21.2) 33.9 (21.8)b 24.1 (24.9)a 21.4 (23.0) 26.9 (26.5)b
Peripheral, % 63.8 (17.4)a 59.8 (17.5) 67.3 (16.5)b 63.4 (17.2)a 61.8 (17.4) 65.1 (17.5)b
Post-BD concavity: mean (sD)
Central, % 25.9 (23.2)a 22.0 (22.7) 29.4 (23.1)b 16.7 (26.0)a 12.9 (24.3) 20.7 (27.1)b
Peripheral, % 58.4 (19.7)a 53.6 (19.3) 62.7 (19.1)b 56.7 (20.1)a 55.3 (19.3) 58.1 (20.7)
Notes: % predicted was calculated using the reference equations from hankinson et al.34 aSignificant difference (P,0.05) between pre-BD and post-BD. bSignificant difference 
(P,0.05) between ever and never smokers.
Abbreviations: BMI, body mass index; FeF25%–75%, forced expiratory flow between 25% and 75% of the FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; Post-BD, post-bronchodilator; Pre-BD, pre-bronchodilator.
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but not in FVC, and a reduction in the degree of central and 
peripheral concavities.
In both genders, there were strong negative correlations 
between the new measures of concavity and FEV
1
, FEV
1
/
FVC, and FEF
25%–75%
, but not with FVC (Table 2).
Upper limits of normal for concavity 
indices
A total of 268 subjects (131 males and 137 females) were 
classified as normal never smokers (as defined above) and 
their descriptive data are summarized in Table 3. In these 
subjects, the mean value for post-BD central (males, 18.6%; 
females, 9.1%) and peripheral (males, 50.5%; females; 
52.4%) concavities deviated significantly from the “ideal” 
reference value (dotted line in Figure 1) of zero, which prob-
ably reflected an “aging effect” on small airway function in 
our middle-aged and older normal sample. However, and 
perhaps as expected, the ULN for post-BD measurements of 
central (males 56.4%; females 45.8%) and peripheral (males 
77.5%; females 78.1%) concavities were quite large.
reliability and sensitivity of the concavity 
indices
Intraclass (within-subject) correlations for central and periph-
eral concavities were ~0.96, which was similar to FEF
25%–75%
 
and only slightly lower than for FEV
1
, FVC, and FEV
1
/FVC 
(0.99). However, as shown in Table 4, the prevalence of an 
abnormally high degree of central or peripheral concavity 
was substantially greater than the prevalence of an abnor-
mally low FEV
1
, FVC, FEV
1
/FVC, or FEF
25%–75%
. This was 
especially the case in males and against the Hankinson et al34 
normative values, which were used throughout the BOLD 
Figure 2 relationship between lifetime tobacco consumption and post-BD spirometry and concavity, expressed as the difference relative to never smokers (nil pack-years).
Note: P-values refer to all points below the arrow.
Abbreviations: FeF25%–75%, forced expiratory flow between 25% and 75% of the FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; post-BD, 
post-bronchodilator.
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Table 2 spearman rank correlations for associations between post-BD concavity and spirometric variables
Males (n=424) Females (n=466)
Central Peripheral Central Peripheral
rho P-value rho P-value rho P-value rho P-value
FeV1 (% predicted) -0.476 ,0.001 -0.506 ,0.001 -0.506 ,0.001 -0.505 ,0.001
FVC (% predicted) -0.058 0.233 -0.112 0.021 -0.126 0.006 -0.122 0.008
FeV1/FVC -0.755 ,0.001 -0.789 ,0.001 -0.710 ,0.001 -0.793 ,0.001
FeF25%–75% (% predicted) -0.734 ,0.001 -0.702 ,0.001 -0.748 ,0.001 -0.735 ,0.001
Abbreviations: FeF25%–75%, forced expiratory flow between 25% and 75% of the FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; post-BD, 
post-bronchodilator.
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program and elsewhere (which specifically take into account 
the aging effect in a way that GOLD1 does not for FEV
1
/
FVC values). Thus, these concavity indices substantially 
increase the pick-up of early airflow obstruction, even when 
allowing for the quite wide variation of normal in this aging 
sample. These additional small airway-obstructed subjects 
are located in the right-upper quadrant of the plots shown 
in Figures 3–5.
Detailed inspection of these extra abnormal curves in the 
right upper quadrants suggests that for the most part there was 
just visually obvious scalloping of the MEFV curves, such 
that conventional indices of airway obstruction remained 
relatively unaffected.
relationship to symptoms
We found that 16.6% of both men and women reported exer-
cise limitation due to breathlessness when other spirometric 
indices were normal. Approximately 21% of these individu-
als had abnormal concavity (Table 5). On the other hand, the 
specificity of abnormal concavity indices was high. Over 90% 
of people without exercise limitation due to breathlessness 
had normal concavity indices.
Discussion
We have described a simple and reliable method for quanti-
fying the characteristic scalloping affecting the central and 
peripheral regions of the MEFV curve in chronic airflow 
obstruction, to determine if this would better detect early 
small airway obstruction. We have developed ULN reference 
values and showed that an abnormal degree of concavity was 
a common finding in our middle-aged and older community 
sample, especially in males and in those with a significant 
smoking history.
These concavity indices are statistically related to more 
conventional spirometric values, so broadly as we might 
expect, they reflect the same thing, that is, airflow obstruction. 
On the other hand, we quite commonly detected an abnormal 
MEFV curve when the FEV
1
/FVC ratio and FEF
25%–75%
 were 
within normal limits (Figures 3–5). This, together with our 
finding of imperfect correlations between our indices of con-
cavity and FEV
1
, FEV
1
/FVC, and FEF
25%–75%
, suggests that 
assessing concavity could provide additional physiological 
Table 3 Descriptive data for subjects classified as normala
Males Females
subjects, n 131 137
age, years: mean (sD) 56.1 (10.2) 57.7 (9.4)
height, cm: mean (sD) 176.7 (6.6) 161.8 (6.1)
Weight, kg: mean (sD) 87.0 (14.1) 70.8 (14.3)
BMI, kg/m2: mean (sD) 27.8 (3.9) 27.0 (5.1)
Pre-BD spirometry: mean (sD)
FeV1, l 3.74 (0.68) 2.56 (0.45)
% predicted 101.9 (12.0) 99.6 (12.0)
FVC, l 4.80 (0.83) 3.30 (0.59)
% predicted 100.0 (12.1) 99.9 (12.3)
FeV1/FVC% 78.0 (5.75) 77.8 (5.53)
% predicted 102.0 (6.9) 99.0 (7.1)
FeF25%–75%, l/second 3.52 (1.19) 2.37 (0.77)
% predicted 111.7 (30.6) 98.8 (29.8)
Post-BD spirometry: mean (sD)
FeV1, l 3.85 (0.68) 2.63 (0.46)
% predicted 104.9 (12.0) 102.3 (12.0)
FVC, l 4.80 (0.82) 3.28 (0.58)
% predicted 100.0 (12.0) 99.3 (12.1)
FeV1/FVC% 80.3 (5.44) 80.3 (4.84)
% predicted 105.0 (6.5) 102.3 (6.2)
FeF25%–75%, l/second 3.95 (1.21) 2.72 (0.77)
% predicted 125.9 (31.3) 113.5 (29.9)
Pre-BD concavity: mean (sD)
Central, % 23.9 (19.6) 17.9 (20.4)
Peripheral, % 57.1 (17.1) 59.3 (17.6)
Post-BD concavity: mean (sD)
Central, % 18.6 (20.5) 9.1 (21.0)
Peripheral, % 50.5 (18.8) 52.4 (18.3)
Notes: anormal subjects were selected according to the following criteria: 1) never 
smoked; 2) ,12% change in FeV1 and FVC post bronchodilator; 3) no diagnosis of 
asthma, chronic bronchitis, or emphysema by doctor; and 4) not limited in their 
capacity to perform moderate daily activities.
Abbreviations: BMI, body mass index; FeF25%–75%, forced expiratory flow between 
25% and 75% of the FVC; FeV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity; Post-BD, post-bronchodilator; Pre-BD, pre-bronchodilator.
Table 4 Prevalence of abnormal post-BD concavities (central 
and peripheral) and abnormal spirometric variables
Criteriaa Males 
(n=424), %
Females 
(n=466), %
abnormal central concavity 12.0 14.6
abnormal peripheral concavity 17.9 14.6
abnormal FeV1 8.0 6.2
abnormal FVC 8.3 5.6
abnormal FeV1/FVC 9.2 9.4
abnormal FeV1/FVC (gOlD) 16.5 13.1
abnormal FeF25%–75% 4.5 6.2
abnormal central + FeV1/FVC normal 6.1 (+66%) 8.8 (+94%)
abnormal central + FeV1/FVC 
normal (gOlD)
2.6 (+16%) 6.2 (+4.7%)
abnormal peripheral + FeV1/FVC normal 11.3 (+122%) 8.2 (+87%)
abnormal peripheral + FeV1/FVC 
normal (gOlD)
6.1 (+37%) 5.4 (+41%)
abnormal central + normal FeF25%–75% 9.0 (+200%) 10.7 (+172%)
abnormal peripheral + normal FeF25%–75% 14.4 (+320%) 9.9 (+160%)
Notes: Values in brackets indicate the extra percent case pick-up rate of small airway 
obstruction with a specified concavity index. aUpper limit of normal concavity – 
males: central =56.4, peripheral =77.5; females: central =45.8, peripheral =78.1. lower 
limit of normal for spirometric parameters from hankinson et al34 and where 
stated, gOlD.1
Abbreviations: FeF25%–75%, forced expiratory flow between 25% and 75% of the 
FVC; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, 
global initiative for chronic obstructive lung disease; post-BD, post-bronchodilator.
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3573
Concavity and early airflow obstruction
information not available using these spirometric variables. 
In this, we have developed on themes already published18,20–23 
but, in addition, the high specificity of abnormal concavity 
for breathlessness on exercise in people with normal FEV
1
/
FVC and FEF
25%–75%
 (Table 5) suggests that concavity is 
clinically useful for excluding early airway disease as a cause 
of breathlessness.
It was also informative to visualize the MEFV curves 
where concavity was not significantly abnormal, but one or 
more other spirometric indices suggested COPD. Detailed 
examination suggested for the most part abnormalities 
in the central airways and did not necessarily reflect the 
small airway-predominant disease, which is characteristic 
of smokers.
Perhaps, our most important finding was a higher preva-
lence of abnormal concavity compared with abnormal FEV
1
, 
FEV
1
/FVC, and especially FEF
25%–75%
, in our middle-aged 
and older population, especially when using Hankinson’s 
normative spirometry values.34 It was less advantageous 
against GOLD “fixed” FEV
1
/FVC ratio of ,70%, which does 
not take into account the aging effect on airway narrowing,1 
though our regression analyses for concavity measures did 
not show significant aging effects. It will be of interest 
whether an early singular increase in concavity alone is a 
signal for likely progression of airway obstruction to “con-
ventional” COPD with FEV
1
/FVC reduction.
A particular strength of the concavity indices is that 
they seemed more sensitive to small airway narrowing than 
Figure 3 Post-BD relationships between central concavity and FeV1/FVC in males (n=424) and females (n=466).
Notes: The horizontal dotted line is the ULN for central concavity. The vertical dotted line in the two upper plots is the LLN for FEV1/FVC from hankinson et al
34 and for 
the lower two plots, it is the fixed LLN of 70% from GOLD.1 a negative value for FeV1/FVC indicates values below the lln.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, global initiative for chronic obstructive lung disease; lln, lower limit of 
normal; Post-BD, post-bronchodilator; Uln, upper limit of normal.
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FEF
25%–75%
, which is currently used for this purpose. There 
were also few potentially “false negatives” (in the lower 
left panels in Figures 3–5). The presence of other comorbid 
causes of dyspnea, such as heart disease, may explain the 
low sensitivity of this measure, which only detects airflow 
obstruction, but detailed data on comorbidities were not col-
lected. Our concavity measures are also easy to understand 
because they closely match the way most reporters already, 
but imprecisely, visually assess curvature. They intuitively 
tend to take into account inspection of the ideal reference line 
from PEF to end FVC and also take into account vPEF in 
the assessment of MEFV curves. Furthermore, by assuming 
a fixed value for vPEF equal to the mean obtained in this 
study (males, 0.65 L; females, 0.51 L), our curvature indices 
could be directly and easily obtained for current tests and 
any spirometric datasets that included FVC, FEF
50%
, FEF
75%
, 
and PEF.
Of those whose central concavity was normal, 10.9% of 
males (but only 3.2% of females) had an abnormal degree of 
peripheral concavity. This indicated that concavity confined 
to the terminal region of the MEFV curve was uncommon 
but may reflect the very earliest small airways disease. 
The contrasting sole central concave pattern was less com-
mon in males (12.9%) than in females (29.2%), perhaps 
again a reflection of the higher male tobacco consumption. 
We have previously observed this latter pattern in young 
Figure 4 Post-BD relationships between peripheral concavity and FeV1/FVC in males (n=424) and females (n=466).
Notes: The horizontal dotted line is the ULN for peripheral concavity. The vertical dotted line in the two upper plots is the LLN for FEV1/FVC from hankinson et al
34 and 
for the lower two plots, it is the fixed LLN of 70% from GOLD.1 a negative value for FeV1/FVC indicates values below the lln.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, global initiative for chronic obstructive lung disease; lln, lower limit of 
normal; Post-BD, post-bronchodilator; Uln, upper limit of normal.
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adults, and also in lungs that are small relative to chest size 
post lung transplantation, presumably reflecting excessive 
recruitment of lung elastic recoil with radial traction as the 
lung deflates.
The present study has several limitations. Our commu-
nity sample included relatively few people with established 
COPD according to established criteria based on FEV
1
/FVC, 
as one might expect, but has still highlighted that some of 
these individuals did not really have classic COPD with 
generalized airway disease focused physiologically in the 
small airways, but more likely had an obstructive abnormality 
focused in the larger airways only. A clinical population 
more enriched for reduced FEV
1
/FVC should be studied 
to get more numeric information on this group in terms of 
assessing sensitivity and specificity for different measures. 
Our concavity ULN values were based on a relatively small 
number of normal subjects (131 males and 137 females), and 
so they may need to be refined when more data are available. 
Another potential limitation of this study is the straight line 
from PEF to RV, assuming this to be the ideal reference 
line. Such a near-linear descending limb is indeed the most 
common finding in people with normal spirometry,33 and we 
believe that our assumption is justified in providing a zero 
reference for concavity. Further research is also needed to 
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Figure 5 Post-BD relationships between central and peripheral concavities and FeF25%–75% in males (n=424) and females (n=466).
Notes: The horizontal line is the ULN for central (upper plots) and peripheral (lower plots) concavities. The vertical dotted line is the LLN for FEF25%–75% from hankinson 
et al.34 a negative value for FeF25%–75% indicates values below the lln.
Abbreviations: FeF25%–75%, forced expiratory flow between 25% and 75% of the FVC; LLN, lower limit of normal; Post-BD, post-bronchodilator; ULN, upper limit 
of normal.
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compare this new and easily available spirometric index with 
more complex measures, such as the forced oscillation12 and 
multiple-breath nitrogen washout tests,11 which attempt to 
obtain much the same thing, that is, early signals of airway 
disease.
Conclusion
We propose that for the assessment of early “small airway” 
airflow obstruction, this newly updated measurement of 
concavity in the MEFV curve should be incorporated into 
routine spirometry reports and indeed should become the 
standard for defining small airway disease and subclinical 
COPD. Waiting for the FEV
1
/FVC ratio to change may be 
too insensitive and can underestimate the amount of disease 
present both in the individual and in the community.
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